THERAPY DOSSIER · th-189522c95175

Mirogabalin

Drug · Alpha2-delta ligand (gabapentinoid) for neuropathic pain.

Evidence & regulatory context

Mechanism: Alpha2-delta ligand (gabapentinoid) for neuropathic pain.
Target: CHEMBL1919 (Cav alpha2delta-1); CHEMBL3896 (alpha2delta-2)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL3545125 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Tarlige; DS-5565
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03901352 ↗PHASE3completed

Mirogabalin in Central Neuropathic Pain

Central Neuropathic Pain

Enrolment: 300 · Results not recorded

NCT07157852 ↗NArecruiting

Pregabalin vs Mirogabalin in Fibromyalgia

Fibromyalgia

Enrolment: 674 · Results not recorded

NCT06711978 ↗NAnot yet recruiting

Mirogabalin vs Duloxetine in Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy

Enrolment: 66 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30396385 ↗2018Reported benefit

Analgesic effects of the novel alpha2delta ligand mirogabalin in a rat model of spinal cord injury.

RatSpinal cord injuryCompressionSprague-DawleyMaleOral2.5, 5 or 10 mg/kg28 days after spinal cord injury

Model: Acute compression of the spinal cord at the T6/7 level with a microvascular clip; testing 28 days after injury

A single oral dose of mirogabalin significantly raised the paw withdrawal threshold and the paw withdrawal threshold area under the curve relative to control, with effects still significant at 6 to 8 h after administration.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…